BRAIN.Q, an Israeli health-tech company, has announced the launch of Israel’s first home clinic for stroke recovery, powered by its AI-based electromagnetic therapy system, following regulatory approval.
The system has received Breakthrough Device designation from the United States Food and Drug Administration (FDA), CE Mark certification in the European Union, and AMAR approval from Israel’s Health Ministry as a prescribed therapy for reducing post-stroke disability.
The launch of BRAIN.Q coincides with the presentation of new clinical findings at the International Stroke Conference and the appointment of UCLA’s Prof. Jeffrey L. Saver as the company’s medical director.
Yotam Drechsler, BRAIN.Q’s co-founder and CEO, said that the brain is “our most precious resource” and described the launch as a milestone in providing care that promotes and preserves long-term brain health.
Strokes remain the leading cause of long-term disability in Israel. According to the 2024 State Comptroller’s report, approximately 18,400 new stroke cases are recorded annually, with over 100,000 stroke survivors living in the country.
The treatment combines a wearable helmet delivering low-intensity, frequency-tuned electromagnetic stimulation with a personalized rehabilitation program managed through a cloud-based AI platform. The system monitors patients in real-time, allowing clinicians to adjust therapy remotely, while enabling daily independent use at home.
According to a meta-analysis presented at the American Heart Association’s International Stroke Congress, 34 percent of patients who began treatment with moderate-to-severe disability achieved full functional independence within months, compared to 12% in the control group.
Approximately 85% of treated patients showed measurable improvement. The clinical model was validated in controlled trials at 15 leading medical centers worldwide, such as institutions affiliated with Harvard, Cornell, Columbia, and the University of California Los Angeles (UCLA).
More than 8,000 sessions have been conducted to date, with no serious treatment-related adverse events reported.
Globally, several companies are exploring similar non-invasive neuro-recovery technologies. Flow Neuroscience, based in Sweden, focuses on transcranial direct current stimulation for depression and cognitive disorders, while Neuroelectrics, headquartered in Barcelona, offers EEG-guided neurostimulation for rehabilitation and research purposes.
Unlike these competitors, BRAIN.Q emphasizes a fully integrated home clinic model with a subscription-based service and real-time remote monitoring, which its founders argue could significantly improve adherence and outcomes.
Alongside the launch, BRAIN.Q announced Saver’s appointment as medical director. Saver, already the director of the UCLA Comprehensive Stroke and Vascular Neurology Program, said, “Israel is one of the world’s most advanced medical and scientific ecosystems, making it the natural choice to launch such a groundbreaking model. After years of dramatic progress in acute stroke care, long-term brain recovery remains the missing link in global healthcare.”
He added that the system introduces “a new, evidence-based, plasticity-oriented care model that puts the patient at the center.”